Treatment of patients with epidermal growth factor receptor(EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy and in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease and with platinum-based chemotherapy for recurrent and/or metastatic disease.